Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | TEC | P42680 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745551 | 0.86 | BTK (0.38) | BTKMAPTKDM4EHTTGRM5 | |
| SCHEMBL31745443 | 0.81 | TNK2 (0.34) | BTKMAPTKDM4EHTTGRM5 | |
| SCHEMBL31745483 | 0.81 | MAPT (0.36) | BTKMAPTKDM4EHTTGRM5 | |
| SCHEMBL31745554 | 0.81 | TNK2 (0.37) | BTKGRM5SYK | |
| SCHEMBL31745472 | 0.80 | BTK (0.40) | BTKEGFR | |
| SCHEMBL31745513 | 0.78 | BTK (0.37) | BTKGRM5EGFRTECITK | |
| SCHEMBL31745492 | 0.74 | GRM5 (0.36) | BTKGRM5TGFBR1EGFR | |
| SCHEMBL31745562 | 0.73 | KDM4E (0.37) | MAPTKDM4EHTTGAA | |
| SCHEMBL29002666 | 0.73 | PARP1 (0.39) | GRM5SYKTGFBR1 | |
| SCHEMBL31745504 | 0.73 | BTK (0.34) | BTKGRM5SYKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
| CN-119451964-A | FGFR2 and FGFR3 inhibitors and uses thereof | 英矽智能科技知识产权有限公司 | 2025-02-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | BTK 178/4885MAPT 2467/4885KDM4E 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.